Home » Stocks » FBRX

Forte Biosciences, Inc. (FBRX)

Stock Price: $38.43 USD -0.56 (-1.44%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 500.27M
Revenue (ttm) 9,000
Net Income (ttm) -60.72M
Shares Out 11.21M
EPS (ttm) -23.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $38.43
Previous Close $38.99
Change ($) -0.56
Change (%) -1.44%
Day's Open 39.71
Day's Range 37.70 - 39.99
Day's Volume 52,277
52-Week Range 0.46 - 252.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 month ago

FB-401 is a unique approach to atopic dermatitis containing three strains of bacteria that have shown the ability to induce tissue repair and reduce inflammation. FB-401 may present efficacy a...

Business Wire - 2 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., C...

Business Wire - 2 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement...

Business Wire - 2 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., C...

Business Wire - 2 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial results...

Business Wire - 2 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2...

Business Wire - 2 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten publ...

Business Wire - 2 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--FORTE BIOSCIENCES ANNOUNCES PRICING OF $40.0 MILLION PUBLIC OFFERING OF COMMON STOCK

Business Wire - 2 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritte...

Business Wire - 3 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administ...

Business Wire - 3 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the first patient has been dose...

Business Wire - 4 months ago

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc.

Benzinga - 4 months ago

Forte Biosciences (NASDAQ: FBRX) shares are trading higher on Friday after getting two upgrades.

About FBRX

Forte Biosciences operates as a clinical-stage dermatology company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company is based in Torrance, California.

Industry
Biotechnology
CEO
Martin Duvall
Employees
6
Stock Exchange
NASDAQ
Ticker Symbol
FBRX
Full Company Profile

Financial Performance

In 2019, FBRX's revenue was $36,000, a decrease of -99.80% compared to the previous year's $18.04 million. Losses were -$63.52 million, 29.7% more than in 2018.

Financial Statements